Regeneron Pharmaceuticals, Inc. (REGN) stock
REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 16/308% above fair value
$951.19−8.22 (-0.86%)
Close on Nov 12, 2026Market cap $98.40BP/E 21.0Yield –
Regeneron Pharmaceuticals ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Regeneron Pharmaceuticals's ebitda for the twelve months ending Sep 30, 2026 was $5.38B, up 27.6% year over year. For fiscal 2025 it was $4.12B, down 7.9% from the year before. Over ten years it grew 12.0% a year on average. The highest annual figure on record is $9.23B in fiscal 2021.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.12B | -7.9% |
| FY2024 | Dec 31, 2024 | $4.47B | +0.1% |
| FY2023 | Dec 31, 2023 | $4.47B | -12.1% |
| FY2022 | Dec 31, 2022 | $5.08B | -45.0% |
| FY2021 | Dec 31, 2021 | $9.23B | +142.2% |
| FY2020 | Dec 31, 2020 | $3.81B | +57.5% |
| FY2019 | Dec 31, 2019 | $2.42B | -9.8% |
| FY2018 | Dec 31, 2018 | $2.68B | +20.6% |
| FY2017 | Dec 31, 2017 | $2.23B | +55.0% |
| FY2016 | Dec 31, 2016 | $1.44B | +8.2% |
| FY2015 | Dec 31, 2015 | $1.33B | +51.4% |
| FY2014 | Dec 31, 2014 | $876.61M | +11.8% |
| FY2013 | Dec 31, 2013 | $784.25M | +58.5% |
| FY2012 | Dec 31, 2012 | $494.65M | – |
| FY2011 | Dec 31, 2011 | -$174.08M | – |
| FY2010 | Dec 31, 2010 | -$77.79M | – |
| FY2009 | Dec 31, 2009 | -$59.90M | – |
| FY2008 | Dec 31, 2008 | -$74.96M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $2.17B | +86.4% |
| Q2 FY2026 | Jun 30, 2026 | $1.42B | +16.7% |
| Q1 FY2026 | Mar 31, 2026 | $766.10M | +6.6% |
| Q4 FY2025 | Dec 31, 2025 | $1.02B | -8.2% |
| Q3 FY2025 | Sep 30, 2025 | $1.16B | -10.6% |
| Q2 FY2025 | Jun 30, 2025 | $1.21B | +2.0% |
| Q1 FY2025 | Mar 31, 2025 | $718.60M | -17.0% |
| Q4 FY2024 | Dec 31, 2024 | $1.12B | +2.8% |
| Q3 FY2024 | Sep 30, 2024 | $1.30B | +7.0% |
| Q2 FY2024 | Jun 30, 2024 | $1.19B | +6.3% |
| Q1 FY2024 | Mar 31, 2024 | $865.50M | -17.3% |
| Q4 FY2023 | Dec 31, 2023 | $1.09B | -12.9% |
| Q3 FY2023 | Sep 30, 2023 | $1.22B | -7.6% |
| Q2 FY2023 | Jun 30, 2023 | $1.12B | -5.5% |
| Q1 FY2023 | Mar 31, 2023 | $1.05B | -21.5% |
| Q4 FY2022 | Dec 31, 2022 | $1.25B | -54.1% |
| Q3 FY2022 | Sep 30, 2022 | $1.32B | -31.5% |
| Q2 FY2022 | Jun 30, 2022 | $1.18B | -65.4% |
| Q1 FY2022 | Mar 31, 2022 | $1.33B | +12.9% |
| Q4 FY2021 | Dec 31, 2021 | $2.71B | +120.9% |
| Q3 FY2021 | Sep 30, 2021 | $1.92B | +72.6% |
| Q2 FY2021 | Jun 30, 2021 | $3.42B | +378.0% |
| Q1 FY2021 | Mar 31, 2021 | $1.18B | +56.1% |
| Q4 FY2020 | Dec 31, 2020 | $1.23B | +68.3% |
| Q3 FY2020 | Sep 30, 2020 | $1.11B | +40.6% |
| Q2 FY2020 | Jun 30, 2020 | $715.20M | +94.5% |
| Q1 FY2020 | Mar 31, 2020 | $756.20M | +42.4% |
| Q4 FY2019 | Dec 31, 2019 | $730.00M | -4.1% |
| Q3 FY2019 | Sep 30, 2019 | $791.40M | +19.5% |
| Q2 FY2019 | Jun 30, 2019 | $367.70M | -43.9% |
| Q1 FY2019 | Mar 31, 2019 | $531.00M | -12.0% |
| Q4 FY2018 | Dec 31, 2018 | $760.90M | +32.7% |
| Q3 FY2018 | Sep 30, 2018 | $662.30M | +10.8% |
| Q2 FY2018 | Jun 30, 2018 | $655.80M | +12.0% |
| Q1 FY2018 | Mar 31, 2018 | $603.60M | +28.8% |
| Q4 FY2017 | Dec 31, 2017 | $573.36M | +52.6% |
| Q3 FY2017 | Sep 30, 2017 | $597.65M | – |
| Q2 FY2017 | Jun 30, 2017 | $585.44M | – |
| Q1 FY2017 | Mar 31, 2017 | $468.66M | – |
| Q4 FY2016 | Dec 31, 2016 | $375.82M | – |
See a number that looks wrong?